OpenEvidence has become a leading AI platform used daily by doctors across the United States. Its medical search engine is trusted by more than 40% of physicians, spanning over 10,000 hospitals and clinics nationwide. This widespread adoption makes it the most popular AI tool among healthcare professionals in the country.

Massive Funding Boost and Growing Impact

Recently, OpenEvidence announced it closed a Series D funding round led by Thrive Capital and DST Global. The new investment brings the company’s total funding to nearly $700 million. In December alone, the platform supported around 18 million clinical consultations with verified US doctors, a significant jump from about 3 million monthly consultations a year earlier.

This funding round values OpenEvidence at $12 billion, positioning it as the most valuable healthcare AI company in the world. The company’s rapid growth reflects a strong trust from the medical community and a rising demand for advanced AI tools to assist clinicians.

Revolutionizing Medical Knowledge with AI

OpenEvidence is a specialized AI-powered medical search engine designed to be a “brain extender” for doctors. It provides real-time, citation-linked answers drawn exclusively from the most trusted, peer-reviewed medical literature. This focus ensures the answers are accurate and based on the latest medical research.

According to Daniel Nadler, the founder and CEO, staying current with medical research is time-consuming. He explains that reading only the top journals and guideline updates would take doctors nine hours daily. Without tools like OpenEvidence, they risk missing critical new findings or guidelines. The platform aims to help physicians deliver better patient care efficiently and safely.

Unique Approach and Strategic Partnerships

Unlike many AI systems trained on the entire internet, OpenEvidence limits its training to medical journals and data, enhancing accuracy and trustworthiness. Early on, it formed exclusive partnerships with major medical organizations like the New England Journal of Medicine, the American Medical Association, the National Comprehensive Cancer Network, and the American College of Cardiology. These collaborations give OpenEvidence direct access to authoritative medical content.

This strategic access allows the platform to answer questions with high precision, using content directly from leading journals. It results in more reliable responses, which builds confidence among physicians. The company plans to use the new funding to expand its research and development efforts, particularly around its multi-AI agentic architecture.

This architecture involves specialized AI models focused on different medical fields, similar to expert teams in top hospitals. A central “conductor” AI dynamically routes questions to the most relevant specialist model, ensuring the response is as accurate and detailed as possible. This orchestration of AI models aims to deliver the highest quality medical answers available today.

Overall, OpenEvidence is pushing the boundaries of how AI can support healthcare professionals. By combining trusted medical sources with advanced AI technology, it strives to improve patient outcomes and save lives through better-informed clinical decisions.

Inspired by

• https://ai-techpark.com/openevidence-raises-250-mn-to-build-medical-superintelligence-for-doctors/